City Therapeutics, Inc., a biopharmaceutical company leading the future of RNA interference (RNAi)-based medicine, today ...

SanegeneBio is responsible for discovering and identifying optimised RNAi molecules for each programme through its LEAD ...

RNA interference using small interfering RNAs (siRNAs) has become a mainstay of functional gene characterization and has ...

A record-breaking 4,432 scientific abstracts accepted at the American Heart Association’s meeting here adorned posters, ...

Some stocks are similar to the tortoise in Aesop's famous fable, "The Tortoise and the Hare." Others are like the hare. But ...

Using RNA to interfere with a gene’s expression of disease-causing proteins is a validated therapeutic approach, but so far, the products in this drug class only address liver proteins. Reducing ...

RNA interference (RNAi) is a fundamental cellular mechanism that regulates gene expression by inducing sequence-specific mRNA degradation. Researchers could utilize the RNAi as a powerful tool to ...

Responsible for global chickpea losses of around USD 330 million annually, the pest not only threatens chickpeas but also ...

Within each cell, there is a constant struggle between life-sustaining molecules and molecules that could hasten its demise.

Lilly teams up with SanegeneBio in a US$1.2 billion RNAi deal to develop tissue-targeted metabolic therapies using ...

Live webcasts of the analyst-led fireside chats can be accessed by visiting “Investor Events” on the Investors section of the Wave Life Sciences website: ...